利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.019 秒)

    Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
    1.
    发明授权
    Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles 失效
    药物从预先形成的多孔聚合物微粒的控制递送

    公开(公告)号：US5470582A

    公开(公告)日：1995-11-28

    申请号：US18850

    申请日：1993-02-05

    申请人： Andreas Supersaxo ,  Jim H. Kou

    发明人： Andreas Supersaxo ,  Jim H. Kou

    IPC分类号： A61K9/00 ,  A61K9/16 ,  A61K9/52

    CPC分类号： A61K9/1647 ,  A61K9/0009 ,  A61K9/1623

    摘要： A controlled release pharmaceutical composition comprising a physiologically active agent dispersed in preformed porous polymeric microparticles is provided. The active agent concentration may be up to about 10% by weight to achieve controlled release. Each of the porous microparticles has a plurality of preformed pores into which active agent is loaded and from which the active agent is subsequently released to the environment of use. The compositions are capable of delivering physiologically effective amounts of active agent for at least about thirty days, which delivery may be reversibly controlled by exposure to ultrasound.

    摘要翻译： 提供了包含分散在预成型多孔聚合物微粒中的生理活性剂的控释药物组合物。 活性剂浓度可高达约10重量％以实现控制释放。 每个多孔微粒具有多个预成形孔，活性剂被加载到其中，活性剂随后从其中释放到使用环境中。 组合物能够递送生理有效量的活性剂至少约30天，该递送可以通过暴露于超声波而被可逆地控制。

    Microemulsion preconcentrate, microemulsion and use thereof
    2.
    发明授权
    Microemulsion preconcentrate, microemulsion and use thereof 有权
    微乳液预浓缩液，微乳液及其用途

    公开(公告)号：US08158134B1

    公开(公告)日：2012-04-17

    申请号：US10110212

    申请日：2000-10-20

    申请人： Andreas Supersaxo ,  Marc Antoine Weder ,  Hans Georg Weder

    发明人： Andreas Supersaxo ,  Marc Antoine Weder ,  Hans Georg Weder

    IPC分类号： A61K9/00 ,  A61K9/46 ,  C11D17/00

    CPC分类号： A61K9/1075 ,  A61K9/4858 ,  A61K38/13

    摘要： The invention relates to compositions in the form of microemulsion preconcentrates that contain (a) a mixture that consists of a medium-chain triglyceride and an omega-9 fatty acid and/or an omega-6 fatty acid; and (b) a surface-active component that contains a polyoxethylene tenside. When contacted with water or with an aqueous medium these microemulsion preconcentrates form microemulsions. The microemulsions of the O/W type have an average particle size below 150 nm, preferably below 100 nm. The inventive microemulsion preconcentrates and microemulsions are suitable for use as vehicles for substances, namely active agents, that are hardly soluble in water, but soluble in components (a) and/or (b). In the aqueous phase, said microemulsions may contain water-soluble substances.

    摘要翻译： 本发明涉及微乳液预浓缩物形式的组合物，其含有（a）由中链甘油三酯和ω-9脂肪酸和/或ω-6脂肪酸组成的混合物; 和（b）含有聚氧乙烯表面活性剂的表面活性成分。 当与水或水介质接触时，这些微乳液预浓缩物形成微乳液。 O / W型的微乳液的平均粒度小于150nm，优选低于100nm。 本发明的微乳液预浓缩物和微乳液适用于难溶于水但可溶于组分（a）和/或（b）的物质即活性剂的载体。 在水相中，所述微乳液可含有水溶性物质。

    Use of nanodispersions in pharmaceutical end formulations
    3.
    发明申请
    Use of nanodispersions in pharmaceutical end formulations 有权
    在药物末端制剂中使用纳米分散体

    公开(公告)号：US20060292191A1

    公开(公告)日：2006-12-28

    申请号：US11446844

    申请日：2006-06-05

    申请人： Andreas Supersaxo ,  Hans Weder ,  Dietmar Huglin ,  Joachim Roding

    发明人： Andreas Supersaxo ,  Hans Weder ,  Dietmar Huglin ,  Joachim Roding

    IPC分类号： A61K9/00

    CPC分类号： A61K9/1075 ,  A61K9/4858 ,  A61K9/4866 ,  Y10S514/846 ,  Y10S514/937 ,  Y10S514/938 ,  Y10S514/941 ,  Y10S514/947

    摘要： A nanodispersion comprises (a) a membrane-forming molecule, (b) a coemulsifier and (c) a lipophilic component, in pharmaceutical end formulations, the nanodispersion being obtainable by (α) mixing the components (a), (b) and (c) until a homogeneous clear liquid is obtained, and (β) adding the liquid obtained in step (α) to the water phase of the pharmaceutical end formulations, where steps (α) and (β) may be carried out without high energy mixing or homogenization. The nanodispersions prepared according to this invention are suitable as transport vehicles for pharmaceutical active agents.

    摘要翻译： 纳米分散体包含（a）在药物末端制剂中的成膜分子，（b）共乳化剂和（c）亲脂性组分，所述纳米分散体可通过（α）混合组分（a），（b）和（ c）直到获得均匀的透明液体，和（β）将步骤（α）中获得的液体加入到药物末端制剂的水相中，其中步骤（α）和（β）可以在没有高能量混合的情况下进行 或均质化。 根据本发明制备的纳米分散体适合用作药物活性剂的运输工具。

    Topically applied pharmaceutical formulation
    6.
    发明授权
    Topically applied pharmaceutical formulation 失效
    局部应用药物制剂

    公开(公告)号：US06420394B1

    公开(公告)日：2002-07-16

    申请号：US09057305

    申请日：1998-04-08

    申请人： Andreas Supersaxo

    发明人： Andreas Supersaxo

    IPC分类号： A61K4700

    CPC分类号： A61K9/0014 ,  A61K31/192 ,  A61K31/196 ,  A61K31/405 ,  A61K47/02 ,  A61K47/10 ,  A61K47/32 ,  A61K47/38 ,  Y10S514/944

    摘要： The present invention relates to a novel pharmaceutical formulation for the topical application of drugs, particularly non-steroidal anti-inflammatory drugs (NSAID's), comprising a therapeutically effective amount of a drug, sodium phosphate buffer, and, optionally, an alcoholic solvent. It has been found that by the addition of sodium phosphate buffer to such formulations, the permeation of the NSAID can be significantly improved.

    摘要翻译： 本发明涉及用于局部施用药物，特别是非甾体抗炎药（NSAID's）的新型药物制剂，其包含治疗有效量的药物，磷酸钠缓冲液和任选的醇溶剂。 已经发现，通过向这种制剂中加入磷酸钠缓冲液，NSAID的渗透可以显着改善。